naltrexone and Muscular Weakness

naltrexone has been researched along with Muscular Weakness in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adam, J; Cohen, D; Ewers, D; Hajj, R; Kungl, T; Mroczek, M; Nabirotchkin, S; Nave, KA; Prukop, T; Sereda, MW; Stenzel, J; Wernick, S	1
Bagherzadeh, AH; Ebrahimi-Dariani, N; Farahvash, MJ; Farhangi, E; Froutan, H; Ghofrani, H; Mansour-Ghanaei, F; Mirmomen, S; Nasiri-Toosi, M; Pourrasouli, Z; Taheri, A	1

Trials

1 trial(s) available for naltrexone and Muscular Weakness

Article	Year
Effect of oral naltrexone on pruritus in cholestatic patients. World journal of gastroenterology, 2006, Feb-21, Volume: 12, Issue:7 Topics: Administration, Oral; Adult; Aged; Cholestasis; Dizziness; Headache; Humans; Middle Aged; Muscle Weakness; Naltrexone; Nausea; Pain Measurement; Placebos; Pruritus; Single-Blind Method; Substance Withdrawal Syndrome; Surveys and Questionnaires	2006

Other Studies

1 other study(ies) available for naltrexone and Muscular Weakness

Article	Year
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PloS one, 2019, Volume: 14, Issue:1 Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Animal; Drug Combinations; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Muscle Weakness; Myelin Proteins; Naltrexone; Neural Conduction; Phosphatidylinositol 3-Kinases; Proof of Concept Study; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Schwann Cells; Signal Transduction; Sorbitol	2019

Article

Year

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

PloS one, 2019, Volume: 14, Issue:1

Topics: Animals; Axons; Baclofen; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Animal; Drug Combinations; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Muscle Weakness; Myelin Proteins; Naltrexone; Neural Conduction; Phosphatidylinositol 3-Kinases; Proof of Concept Study; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Schwann Cells; Signal Transduction; Sorbitol

2019